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ultrasound could then be directed toward the anatomical
regions where the lesion is located. Most regions of the brain
can be accessed through the temporal acoustic window, with
the exception of distal areas of the frontal and occipital lobes.
Focussed ultrasounds are known to transiently increase the
permeability of the BBB (3) and, therefore, allow passage of
OA-GcMAF that is a relatively lipophilic molecule thanks to
the presence of oleic acid. The procedure lasts 5-15 min,
causes no discomfort or side effects and can be repeated
continuously or in cycles. The procedure can be safely
performed before, during or after other anti-neoplastic
treatments.
1 Ruggiero M et al: Oleic Acid, deglycosylated vitamin d-
binding protein, nitric oxide: a molecular triad made lethal
to cancer. Anticancer Res 34(7): 3569-3578, 2014.
2 Bradstreet JJ et al: A new methodology of viewing extra-
axial fluid and cortical abnormalities in children with autism
via transcranial ultrasonography. Front Hum Neurosci 7:
934, 2014.
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A woman was diagnosed with mammary adenocarcinoma in
the right breast in 1985 at the age of 37, followed by
quadrantectomy, lymphadenectomy and irradiation. In 1999, an
adenocarcinoma was diagnosed in the left breast, followed by
ample resection and anti-oestrogen receptor treatment for 6
years. In April 2014, an infiltrating adenocarcinoma was
diagnosed in the right breast that had been operated in 1985.
Pre-operative biopsy showed weak positivity for progesterone
receptor (PgR, <1%) and high positivity for the oncogene
HER2 (>10%, score 2+). With the goal of boosting her
immune system during the 3 weeks preceding surgery,
glycosylated oleic acid/vitamin D-binding protein (OA-
GcMAF) was administered by subcutaneous injections,
nebulisation and with a fermented milk product rich in OA-
GcMAF. No drug was administered in the 3 weeks preceding
surgery, nor had the patient received any treatment for the
previous 8 years. Following right mastectomy, analysis of the
surgical specimen showed no positivity for HER2 expression
(negative, score 0) and significant increase in positivity of PgR,
from <1% to 20%. These results indicate that OA-GcMAF
treatment suppressed oncogene expression and induced
differentiation of cancer cells. Introduction: The healthy
properties of oleic acid (OA) in breast cancer have been known
for centuries (1) and recent evidences suggest that these
properties are amplified by association of OA with proteins
such as α-lactalbumin and lactoferrins. These proteins form
OA-protein complexes that exhibit highly selective anti-tumour
activity in vitro and in vivo (2). We recently demonstrated that
also a serum protein with the capability to bind OA shows
anticancer effects; this is the glycosylated vitamin D-binding
protein also known as Gc-protein-derived macrophage
activating factor or GcMAF (3). This protein binds both OA
and vitamin D and exerts its immune-stimulating and
anticancer effects through cross-talk with the vitamin D
receptor (4). Here we report a clinical observation suggesting
that OA-GcMAF, that is GcMAF-complexed with OA,
suppresses the expression of a major oncogene involved in
human breast cancer that is the human epidermal growth factor
receptor 2 (HER2). Patients and Methods: A woman was
diagnosed with mammary adenocarcinoma in the right breast in
1985 at the age of 37, followed by quadrantectomy,
lymphadenectomy and irradiation. In 1999, an adenocarcinoma
was diagnosed in the left breast, followed by ample resection
and anti-oestrogen receptor treatment for 6 years. In April
2014, an infiltrating adenocarcinoma was diagnosed in the right
breast that had been operated in 1985. With the goal of
boosting her immune system during the 3 weeks elapsing
between biopsy and programmed surgery, OA-GcMAF
(Goleic®, Immuno Biotech Ltd.) was administered by
subcutaneous injections (880 ng) and nebulisation (880 ng) as
indicated in (3). The patient followed a nutritional regime based
on a low carbohydrate, high protein diet (5). To this end, the
patient was provided with food containing only 2%
carbohydrates (Le Gamberi Foods, Forlì, Italy), and with
essential aminoacids (Master Aminoacid Pattern®, dr. reinwald
healthcare gmbh, Schwarzenbruck, Germany) (6). The patient
was also provided with a fermented milk product containing
colostrum and microorganisms known to produce OA-GcMAF
from the Gc-protein present in milk (Bravo Probiotic®, Les
Alpes, Wellington, NZ). No drug was administered or was
programmed in the 3 weeks preceding surgery, nor had the
patient received any treatment for the previous 8 years. The
analyses on HER2 and other gene expression on the biopsy and
surgical specimens were performed by the laboratory of the
University Hospital of Careggi of the Italian Public Health
Service, in Firenze, Italy. Analyses were performed according
to the European standards of quality (UNI EN ISO 9001:2008)
and were examined and countersigned by four different
professionals. The original documents are conserved in the
archives of the Department of Biomedicine of the Careggi
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Hospital (Molecular Diagnostic and Pathologic Histology). The
patient gave the informed consent to the treatment as well as
to this description of her results. Surgery was performed at the
Division of General Surgery n. 2 of the University Hospital of
Careggi. Results: Amplification or overexpression of HER2
plays an important role in the development and progression of
breast cancer and has become an important biomarker and
target of therapy (7) since it is strongly associated with
increased disease recurrence and a poor prognosis (8).
Consistent with the aggressive nature of the cancer in this
patient, pre-operative biopsy on four specimens collected under
ultrasound guidance showed significant positivity for HER2
assessed by the polyclonal antibody A 0485 with >10% of
positivity and a score of 2+ (Figure 1). After 3 weeks of OA-
GcMAF treatment and subsequent mastectomy, analysis of the
surgical specimen showed no positivity for HER2 expression
(negative, score 0; Figure 1), thus indicating complete
suppression of oncogene expression. Study of the expression
of progesterone receptor (PgR, clone 1E2) was consistent with
such a reversal of the neoplastic phenotype. PgR expression in
the biopsy was low (<1%), a finding consistent with poor
differentiation and aggressiveness. However, in the surgical
specimen taken after the 3 weeks of treatment with OA-
GcMAF, PgR expression was significantly increased to 20%
(Figure). The selectivity of these effects was confirmed by a
study of the expression of Ki67 and estrogen receptor (30%
and 90%, respectively) that did not show any change following
OA-GcMAF treatment (Figure). Discussion: These results
demonstrate that OA-GcMAF, administered by subcutaneous
injections, aerosol or in a functional food product, suppressed
the expression of HER2, an oncogene which plays a key role in
the aetiology, invasive progression and metastasis in breast
cancer. This effect was paralleled by increase of PgR
expression, thus indicating that OA-GcMAF treatment induced
healthy differentiation of cancer cells. We hypothesize that
these multifaceted effects on the regulation of gene expression
in human breast cancer are due to the peculiar association of
OA with GcMAF that is an association between two molecules
endowed with anticancer properties. In fact, OA has been
shown to down-regulate HER2 expression in cancer cell lines
(9) and we demonstrated that GcMAF inhibits human breast
cancer cell proliferation and reverts their malignant phenotype
(10). We hypothesize that OA-GcMAF, but not OA or GcMAF
taken singularly, interacts with the HER2 protein through
hydrophobic interaction between the amino-terminal of
GcMAF and the extracellular region of HER2, and between the
OA-binding region of GcMAF and the plasma membrane (4).
In fact, in the stretch of aminoacids between position 17-46 of
GcMAF, and position 243-273 of HER2, there is a high density
of hydrophobic aminoacids that may favour selective binding.
Whatever the case, these results indicate that the effects of OA-
GcMAF in cancer are due to a multiplicity of actions that
involve suppression of oncogene expression.
Figure. Level of expression of HER2, progesterone receptor
(PgR), Ki67 protein and estrogen receptor (ER). 
“Before”, indicates level of expression observed on the biopsy
samples obtained 3 weeks before surgery and before any
treatment. “After”, indicates level of expression observed on
surgical specimens after OA-GcMAF treatment. Level of
expression is expressed as percentages as in the original
reports. The axis on the left (0-50%) refers to HER2, PgR and
Ki67. The axis on the right (0-100%) refers only to ER. The
actual levels were: HER2, before: >10%, score 2. HER2, after:
negative, score 0. PgR, before: <1%. PgR, after: 20%. Ki67
before and after: 30%. ER, before and after: 90%. 
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Adenocarcinoma of the pancreas still carries a dramatically
poor prognosis and the survival rate for this disease has not
improved substantially in the past 40 years. Therefore, new
treatment options are urgently needed and this need motivates
oncologists to search for novel approaches such as
immunotherapy. Here we report two clinical cases successfully
treated with an integrative immunotherapeutic approach based
on oleic acid bound to glycosylated vitamin D-binding protein
(OA-GcMAF). Considering that immune suppression induced
by pancreatic cancer is one of the main causes for resistance
to chemotherapy and targeted therapy, this novel
immunotherapeutic approach has the potential for
revolutionising the field of pancreatic adenocarcinoma
treatment. Introduction: Adenocarcinoma of the pancreas is,
after colorectal cancer, the second most common digestive
cancer in the USA where it represents the fourth leading cause
of cancer-related death in both genders. In Europe,
adenocarcinoma of the pancreas is the sixth most frequent
cancer and is predicted to become the fourth cause of cancer
death in both sexes in due course in the European Union (1, 2).
Patients with pancreatic adenocarcinoma have an especially
poor prognosis with a 5-year survival rate of <1% and a
median survival of 4-6 months. Patients with a metastatic
disease are usually treated with chemotherapy that is minimally
effective (3). It has been demonstrated that pancreatic cancer-
induced immune suppression is the main cause for this
dramatically poor prognosis and, therefore, it has been
proposed that immunotherapies may be particularly effective
in this type of cancer (4). We recently demonstrated that
immunotherapy based on oleic acid (OA) bound to
glycosylated vitamin D-binding protein (OA-GcMAF) is
effective in a variety of cancers (5); here we describe two
clinical cases demonstrating that OA-GcMAF has therapeutic
efficacy also in pancreatic adenocarcinomas. Patients and
Methods: Patients with adenocarcinoma of the pancreas were
treated with OA-GcMAF-based integrative immunotherapy
according to the “Good practice in prescribing and managing
medicines and devices” effective February 2013. The
approaches described below, aimed at strengthening the
immune system and reducing tumour growth, are considered
complementary to other anti-neoplastic therapeutic procedures.
OA-GcMAF complexes (GOleic) were prepared in-house at
Immuno Biotech Ltd as previously described (5). The protocol
for pancreatic adenocarcinoma was the following: OA-GcMAF
(880 ng/day) was administered by subcutaneous injections in
proximity of the inguinal lymphnodes (440 ng in each side)
under ultrasound guidance. OA-GcMAF (880 ng) was also
administered daily by nebulisation (880 ng dissolved in 5 ml
saline). Suppositories containing 200 ng OA-GcMAF were
administered daily. The total amount of daily OA-GcMAF was
1960 ng, an amount consistent with the procedure described by
Nonaka et al. (6). Patients were provided with supplementation
of vitamin D3, 20.000 IU per day, and they were taught to
drink at least 2 litres of water per day. Patients followed a
nutritional regime based on a diet very low in carbohydrates,
and high in proteins (7). This regimen included
supplementation with essential aminoacids (Master Aminoacid
Pattern, dr. reinwald healthcare gmbh, Schwarzenbruck,
Germany). Considering that probiotics are efficient
immunopotentiators and have a role in cancer prevention (8),
patients were provided with a probiotic fermented milk product
containing colostrum and microorganisms known to produce
natural OA-GcMAF during the fermentation process (Bravo
Probiotic, Les Alpes, Wellington, NZ). Finally, considering the
role of low-dose acetylsalicylic acid in cancer prevention (9),
patients were provided with 100 mg of such a principle per
day. Results: Clinical case #1. A 58-year-old lady was
diagnosed with pancreatic adenocarcinoma localised in the
body of the pancreas. The lesion could be detected by
ultrasonography and it appeared as a roundish mass of 0.924
ml of calculated volume (Figure 1A). After two weeks of
treatment as described above, the calculated volume of the
mass was reduced to 0.517 ml that is about 39% (Figure 1B).
The patient did not report any side effect: her body weight and
lean mass increased during the two weeks of treatment.
Clinical case #2. A 73-year-old man was diagnosed with
metastatic pancreatic adenocarcinoma. Previous CT scans had
evidenced peritoneal metastases. The patient was overweight
and presented with an insulin-dependent diabetes. Due to the
morphological constitution of the patient, the primary
pancreatic lesion could not be evidenced by ultrasonography.
However, a hypo-echoic roundish mass in the abdomen,
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